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Pn behalf of the co-chairs of the first Innovation in
ntervention or i2 Summit—William O’Neill, MD, FACC,
ed Feldman, MD, FACC, FSCAI, and myself—I will be
iscussing the highlights of our inaugural meeting, attended
y more than 4,000 individuals, which was far more than
nvisioned. This first i2 Summit attracted 743 submitted
bstracts, of which 230 were selected for presentation.
TENTING
ivotal randomized trials have shown the safety and efficacy
f drug-eluting stents to reduce restenosis in patients
ndergoing percutaneous coronary intervention (PCI).
owever, these drug-eluting stent trials systematically ex-
luded patients with acute myocardial infarction (MI) based
n their high-risk profile. Now we have the results of the
aclitaxel-Eluting Stent Versus Conventional Stent in ST-
egment Elevation Myocardial Infarction (PASSION) trial
1). This was a randomized comparison of the Taxus
aclitaxel-eluting stent (PES) compared with a bare-metal
tent (BMS), which has already been shown to be safe and
ffective in patients with a recent MI. At one year, there was
o statistical difference in major adverse cardiac events
MACE) between the two PASSION groups (PES 8.7%
s. BMS 12.6%; p 0.12), although it should be noted that
he MACE rate was lower than expected in the BMS arm.
lthough the primary end point was similar, the hazard
atio of 0.68 was clinically meaningful and stent thrombosis
t one year, although low, was similar in the two treatment
roups. Overall, the PES system in patients with ST-
egment elevated MI was safe and at least as effective as
MS placement in this late-breaking clinical trial.
A similar group of patients were enrolled in the Trial to
ssess the Use of the Cypher Stent in Acute Myocardial
nfarction Treated With Angioplasty (TYPHOON) trial,
hich evaluated sirolimus-eluting stents (SES) for primary
CI in acute MI patients (2). Patients were randomized to
ES (n  355) or BMS (n  357). At one year, there was
49% reduction in the primary end point of target vessel
ailure with SES (7.3% vs. 14.3%; p  0.0036), largely
ttributable to a reduction in target vessel revascularization
3.7% vs. 12.6%; p 0.001). Although comparable between
he groups, the incidence of stent thrombosis was higher
han expected by the investigators, suggesting perhaps the
ypercoagulable state of ST-segment elevated MI patients.
he combination of rapid reperfusion via primary PCI and
tenting, combined with glycoprotein (GP) IIb/IIIa inhib-
tors (used in 70% of the patient population), plusp
From the Cardiac Services of St. Joseph’s Hospital of Atlanta, Atlanta Cardiology
roup of Georgia, Atlanta, Georgia.lopidogrel resulted in a favorably lower rate of death and
epeat MI. Use of SES further increased the long-term
linical benefit of primary PCI, which has been shown to be
he most efficient therapy for acute MI when performed
apidly by an experienced team. Both the PASSION and
YPHOON trials show that drug-eluting stents were safe
nd effective in this very high-risk population.
Late clinical outcomes of stenting in diabetic patients
ere the focus of the Strategic Transcatheter Evaluation of
ew Therapies (STENT) trial (3). These are high-risk
atients prone to restenosis after PCI. For non–insulin-
reated patients with diabetes mellitus, there was no signif-
cant difference at nine months between the two stents in
erms of mortality, MI, target vessel revascularization,
ACE, or subacute thrombosis. The results were very
imilar for insulin-treated patients, although there was a
light trend in MACE rate favoring PES (Fig. 1). This
mportant trial suggests to interventionalists that both the
ES and the SES procedure produce similar favorable
esults in terms of late clinical outcomes in diabetic patients
verall, with restenosis rates comparable to those reported in
rior studies for nondiabetic patients.
Another trial of interest was the Taxus V In-Stent
estenosis (Taxus V ISR) study, a prospective multicenter
andomized trial of 396 patients comparing Taxus PES
n  195) with vascular brachytherapy (n 201) in patients
reated previously with BMS who experienced in-stent
estenosis (4). At nine months, PES proved superior in
educing ischemic target lesion revascularization (TLR)
6.3% vs. 13.9%; p  0.01), ischemic target vessel revascu-
arization (10.5% vs. 17.5%; p  0.46), and overall MACE
11.5% vs. 20.1%; p  0.02). Angiographic restenosis was
4.5% with stenting versus 31.2% with vascular brachyther-
py (p  0.001). Thus, for BMS patients in whom in-stent
estenosis develops, a drug-eluting stent represents a simple,
afe therapy with a high rate of success over nine months.
his is a reassuring option for an otherwise difficult-to-treat
roup of patients.
A novel stent composed of an absorbable magnesium
lloy was the focus of the Clinical Performance and Angio-
raphic Results in Absorbable Metal Stents (PROGRESS-
MS) study, which assessed the feasibility, clinical perfor-
ance, and angiographic results of this absorbable metal
tent (5). Although the study involved only 63 patients,
here were no late incomplete apposition or adverse edge
ffects seen on angiography. There was evidence of a
ignificant reduction in vessel, stent, and lumen volumes as
he stent began to be resorbed (Fig. 2). Still, the
ROGRESS-AMS Investigators met their primary end
oint, which was a four-month MACE event rate30%. In
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ACC 2006 Annual Session Highlights June 6, 2006:D9–12his trial, MACE was defined as cardiac death, nonfatal MI,
nd ischemic-driven TLR. No patient experienced late stent
hrombosis.
The PROGRESS-AMS researchers further suggested
hat the absorbable stent was compatible with magnetic
esonance tomography as well as computed tomography
ollow-up. Intravascular ultrasound was able to detect the
bsorbable stent degradation at four months, and the TLR
ate shown in this trial was comparable with that docu-
ented for BMS. Therefore, this is a very exciting early trial
ooking at a novel stent platform that can be absorbed by the
ody; long-term results will be forthcoming at future i2
eetings.
igure 1. Nine-month clinical outcome for insulin-treated diabetic patients
Abbreviations and Acronyms
ACUITY  Acute Catheterization and Urgent
Intervention Triage Strategy
Timing trial
BMS  bare-metal stent
GP  glycoprotein
ICE  intracardiac echocardiography
MACE  major adverse cardiac events
MI  myocardial infarction
MIST  Migraine Intervention with
StarFlex Technology
PASSION  Paclitaxel-Eluting Stent Versus
Conventional Stent in ST-
Segment Elevation Myocardial
Infarction trial
PCI  percutaneous coronary
intervention
PES  paclitaxel-eluting stent
PFO  patent foramen ovale
PROGRESS-AMS  Clinical Performance and
Angiographic Results in
Absorbable Metal Stents study
SES  sirolimus-eluting stent
STENT  Strategic Transcatheter Evaluation
of New Therapies study
TLR  target lesion revascularization
TYPHOON  Trial to Assess the Use of the
Cypher Stent in Acute
Myocardial Infarction Treated
With Angioplastyrial. Completed nine-month follow-up: 5,566, 93.7%. p  NS for all. Blue b
ACE  major adverse cardiac events; MI  myocardial infarction; TVRDDITIONAL TRIALS AND CASES
relatively complex trial that involved 13,800 patients at a
umber of centers worldwide, compared routine up-front
nitiation of GP IIb/IIIa inhibitors (99% of patients ran-
omized to early initiation) with the selective use of these
gents (in 56% of patients randomized to delayed adminis-
ration). The Acute Catheterization and Urgent Interven-
ion Triage Strategy (ACUITY) Timing Trial was a pro-
pective, randomized study of patients with acute coronary
yndrome (6). There was no difference in net clinical benefit
composite end point occurred in 11.7% of patients in both
roups; p 0.001 for noninferiority), and there were similar
ates of adverse ischemic events at 30 days (7.1% for
pstream use vs. 7.9% for GP IIb/IIIa administration as
eeded, which did not meet the criteria for noninferiority).
he rates of major and minor bleeding were reduced
ignificantly in the delayed cohort. The implications of
hese results will be studied further. In the context of the
ntire ACUITY trial, however, both strategies of upstream
nd selective or delayed use of GP IIb/IIIa inhibitors
howed inferior clinical outcomes compared with the use of
ivalirudin alone (11.7% for both GP IIb/IIIa inhibitor
rms vs. 10.1% for bivalirudin alone, p  0.009).
Another exciting study presented at i2 was the Migraine
ntervention with StarFlex Technology (MIST) trial, a pro-
pective, multicenter, randomized, double-blind, placebo-
ontrolled trial to evaluate the efficacy of patent foramen ovale
PFO) closure with the StarFlex septal repair implant to
revent refractory migraine headaches. There has been a
orrelation seen between the presence of a PFO and
igraine headaches. In the double-blind MIST trial, 73
atients underwent a sham operation and 74 patients had
heir PFO closed (7). Although there was no difference in
omplete cessation of migraines between the groups, more
atients who had their PFO closed versus those undergoing
ham surgery had a 50% or greater reduction in headaches
42% vs. 23%; p  0.038) (Fig. 3). This is the first trial to
how at least some benefit of PFO closure in terms of
educing the incidence of migraines. The MIST Investiga-
ors concluded that with longer follow-up, larger numbers
led in the Strategic Transcatheter Evaluation of New Therapies (STENT)enrol
ars  sirolimus-eluting stent; yellow bars  paclitaxel-eluting stent.
 target vessel revascularization.
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June 6, 2006:D9–12 ACC 2006 Annual Session Highlightsf patients, and perhaps even better closure devices, a second
IST trial may help to validate the treatment trends seen in
his study. Further analysis of the current data also may help
hysicians to determine which patients with migraines may
ave a significant treatment response.
The i2 meeting also included a number of state-of-the-
rt presentations on subjects such as endothelial progenitor
ells; the future of interventional cardiology; coronary stent-
ng, where we are and where we are going; coronary artery
ypass graft versus PCI; the status of various large trials;
ulnerable plaque in the future; devices or drugs; cell
herapy; ST-elevated MI management; and the current
tatus of percutaneous valve therapy. There were also
xciting sessions about emerging technologies, including a
eview of complications.
Finally, it is very helpful when interventional meetings
nclude live cases, and we had the best live cases from
round the world: six centers presenting two and one-half
ays of live cases, or approximately 40 live cases, presented
hroughout our meeting. Among these cases, we saw a
evere high-risk lesion involving a tight carotid stenosis in a
atient with a tracheostomy. Stenting produced an excellent
esult with no sequelae, and the patient went home the
ollowing day. Another case presented a complex bifurcating
igure 2. Clinical Performance and Angiographic Results in Absorbable
arameters. No late incomplete opposition; no adverse edge effect. *p  0.01
external elastic membrane.igure 3. Reduction in headache burden (frequency  duration) in the Migrain
ars  baseline; yellow bars  analysis.eft main stenosis, presented by colleagues in Toulouse,
rance. In this case, excellent results were achieved with a
ifurcating stent in the circumflex and left anterior descend-
ng artery, a very high-risk procedure.
From Belgium, participants observed a complex, very
arge PFO in which the bubble formation on the intracar-
iac echocardiography (ICE) could be seen clearly. The case
sed a combination of angiography and ICE, and angiog-
aphy permitted visualization of the catheter placed across
he PFO from the right atrium to the left atrium. At this
oint, the physicians were able to place the novel StarFlex
evice, which uses nitinol technology, through the PFO;
apture the tissue; and deploy the device to occlude the
FO. The final result showed what a truly remarkable
rocedure this is.
In another case, a combination of ICE and angiography
as used to perform a left atrial appendage occlusion in
hich the catheter was placed using a trans-septal approach
nto the left atrial appendage. A device similar to the
tarFlex device, also made of nitinol, was deployed in the
eft atrial appendage, which was occluded in a patient with
trial fibrillation.
A complex left anterior descending artery aneurysm
upture brought together eight high-volume operators to
al Stents (PROGRESS-AMS) study: volumetric intravascular ultrasound
e bars  post-implantation; yellow bars  four-month follow-up. EEMMet
. Blue Intervention with StarFlex Technology (MIST) trial. p  0.033. Blue
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ACC 2006 Annual Session Highlights June 6, 2006:D9–12ecide how to deal with the challenges of the particular case.
ntravascular ultrasound was used to image the very large
neurysm, which was then excluded with a coronary stent
raft. However, the panel members had different ideas
egarding how to manage this patient, underscoring the
ifficulty in treating these fortunately rare cases.
Finally, only through the i2 mechanism were we able to
how all of these very difficult cases from around the world,
ll successfully done throughout our meeting. All in all, i2
roved to be an outstanding inaugural meeting.
eprint requests and correspondence: Dr. William D. Knopf,
ardiac Services of St. Joseph’s Hospital of Atlanta, Atlanta
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tlanta, Georgia 30342-1701. E-mail: wknopf@acgmd.com.
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